{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:22:21Z","timestamp":1770888141240,"version":"3.50.1"},"reference-count":49,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chongqing Science and Technology Bureau\u2019s Key Technology Innovation Special of Key Industries","award":["csct2022ycjhbgzxm0034"],"award-info":[{"award-number":["csct2022ycjhbgzxm0034"]}]},{"name":"Yunnan Provincial Health Commission\u2019s Reserve Talent Development Program for Medical Disciplines"},{"name":"Scientific Research Fund of Education Department of Yunnan Province","award":["2024J0330"],"award-info":[{"award-number":["2024J0330"]}]},{"name":"Scientific Research Fund of Education Department of Yunnan Province","award":["2025J0247"],"award-info":[{"award-number":["2025J0247"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The enzyme 2\u2032-5\u2032-oligoadenylate synthetase 3 (OAS3) plays a well-established role in antiviral immunity, but its involvement in cancer biology remains poorly understood. This study aimed to comprehensively investigate the expression patterns, mutation characteristics, prognostic significance, functional roles, and therapeutic potential of OAS3 across multiple cancer types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Utilizing multi-omics data from public cancer databases, we analyzed OAS3 expression patterns, survival correlations, immune interactions, pathway enrichment, genomic associations, mutation profiles, and functional validation of OAS3 knockdown in THP-1 cells for apoptosis assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OAS3 expression was significantly upregulated in 32 cancer types, highlighting its context-dependent roles as an oncogene. The expression patterns of OAS3 were found to be stage-specific and cancer-specific across multiple tumor types. Survival analysis revealed that high OAS3 expression was significantly associated with unfavorable prognosis in several cancers. Further analyses demonstrated that OAS3 expression was correlated with immune-related genes, immune checkpoints, tumor stemness, and immune cell infiltration across multiple tumor types. Moreover, gene set enrichment profiling revealed significant involvement of OAS3 in interferon response and immune regulation, with prominent enrichment in Janus kinase-signal transducer and activator of transcription (JAK-STAT) and Notch signaling pathways. Mutation analysis highlighted high mutation frequencies of OAS3 in several cancer types, especially in endometrial cancer and melanoma. Comprehensive molecular profiling further identified significant associations between OAS3 expression levels and key genomic features (tumor mutation burden, homologous recombination deficiency and RNA modification-related proteins). Besides, OAS3\u2019s expression was associated with key processes such as cell cycle regulation and immune evasion, further underscoring its potential as a therapeutic target in lung and breast cancers. Finally, we found that OAS3 was observably related with some mutation types (CEBPA, FLT3 internal tandem duplication, NRAS, and EVI1 expression) in patients with acute myeloid leukemia (LAML). Functional validation through RNA interference demonstrated that OAS3 knockdown significantly induced apoptosis in THP-1 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates that OAS3 acts as a pivotal modulator in the complex network of cancer progression, highlighting its dual role in both tumorigenesis and immune response regulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20805","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:39:55Z","timestamp":1770885595000},"page":"e20805","source":"Crossref","is-referenced-by-count":0,"title":["Pan-cancer multi-omics profiling of OAS3 reveals its immunological and prognostic associations across human cancers"],"prefix":"10.7717","volume":"14","author":[{"given":"Xi","family":"Zhang","sequence":"first","affiliation":[{"name":"Central Laboratory of Yong-Chuan Hospital, Chongqing University of Medical Science, Chongqing, China"},{"name":"Key Laboratory of Laboratory Medical Diagnostics, Chongqing University of Medical Science, Chongqing, China"},{"name":"Department of Clinical Laboratory, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, China"},{"name":"Yunnan Key Laboratory of Laboratory Medicine, Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Central Laboratory of Yong-Chuan Hospital, Chongqing University of Medical Science, Chongqing, China"},{"name":"Key Laboratory of Laboratory Medical Diagnostics, Chongqing University of Medical Science, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Key Laboratory of Laboratory Medical Diagnostics, Chongqing University of Medical Science, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Caner Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Pan","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Laboratory Medicine, Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beizhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Central Laboratory of Yong-Chuan Hospital, Chongqing University of Medical Science, Chongqing, China"},{"name":"Key Laboratory of Laboratory Medical Diagnostics, Chongqing University of Medical Science, Chongqing, China"},{"name":"Clinical Laboratory of the Affiliated Rehabilitation Hospital, Chongqing University of Medical Science,  Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"10.7717\/peerj.20805\/ref-1","doi-asserted-by":"publisher","first-page":"102721","DOI":"10.1016\/j.ctrv.2024.102721","article-title":"If it\u2019s a target, it\u2019s a pan-cancer target: tissue is not the issue","volume":"125","author":"Adashek","year":"2024","journal-title":"Cancer Treatment Reviews"},{"issue":"5","key":"10.7717\/peerj.20805\/ref-2","doi-asserted-by":"publisher","first-page":"e0268967","DOI":"10.1371\/journal.pone.0268967","article-title":"Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies","volume":"17","author":"Alam","year":"2022","journal-title":"PLOS ONE"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biology"},{"issue":"3","key":"10.7717\/peerj.20805\/ref-4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"9","key":"10.7717\/peerj.20805\/ref-5","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/hed.27803","article-title":"Bioinformatics approach combined with experimental verification reveals OAS3 gene implicated in paclitaxel resistance in head and neck cancer","volume":"46","author":"Caglar","year":"2024","journal-title":"Head and Neck"},{"issue":"9","key":"10.7717\/peerj.20805\/ref-6","doi-asserted-by":"publisher","first-page":"e005320","DOI":"10.1136\/jitc-2022-005320","article-title":"Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy","volume":"10","author":"Casarrubios","year":"2022","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"3","key":"10.7717\/peerj.20805\/ref-8","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.3892\/ol.2019.10623","article-title":"Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells","volume":"18","author":"Deng","year":"2019","journal-title":"Oncology Letters"},{"key":"10.7717\/peerj.20805\/ref-9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","article-title":"B cell function in the tumor microenvironment","volume":"40","author":"Downs-Canner","year":"2022","journal-title":"Annual Review of Immunology"},{"issue":"8","key":"10.7717\/peerj.20805\/ref-10","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/10428194.2022.2045594","article-title":"Upregulation of FHL1, SPNS3, and MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia patients with FLT3-ITD mutation","volume":"63","author":"Eshibona","year":"2022","journal-title":"Leukemia and Lymphoma"},{"key":"10.7717\/peerj.20805\/ref-11","doi-asserted-by":"publisher","first-page":"1524801","DOI":"10.3389\/fimmu.2025.1524801","article-title":"Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects","volume":"16","author":"Guo","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.7717\/peerj.20805\/ref-13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.7717\/peerj.20805\/ref-14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/bjh.13898","article-title":"Review: aberrant EVI1 expression in acute myeloid leukaemia","volume":"172","author":"Hinai","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.7717\/peerj.20805\/ref-15","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.7150\/thno.53649","article-title":"Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer","volume":"11","author":"Hu","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nature Reviews: Immunology"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","article-title":"The role of m6A modification in the biological functions and diseases","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/jir.2010.0107","article-title":"The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities","volume":"31","author":"Kristiansen","year":"2011","journal-title":"Journal of Interferon and Cytokine Research"},{"key":"10.7717\/peerj.20805\/ref-19","doi-asserted-by":"publisher","first-page":"815480","DOI":"10.3389\/fcell.2022.815480","article-title":"OAS3 is a co-immune biomarker associated with tumour microenvironment, disease staging, prognosis, and treatment response in multiple cancer types","volume":"10","author":"Li","year":"2022","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.7717\/peerj.20805\/ref-20","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1016\/j.csbj.2022.11.045","article-title":"N(1)-methyladenosine modification in cancer biology: Current status and future perspectives","volume":"20","author":"Li","year":"2022","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"2","key":"10.7717\/peerj.20805\/ref-21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.7717\/peerj.20805\/ref-22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.cca.2018.08.040","article-title":"RAS mutations in acute myeloid leukaemia patients: a review and meta-analysis","volume":"489","author":"Liu","year":"2019","journal-title":"Clinica Chimica Acta"},{"issue":"5","key":"10.7717\/peerj.20805\/ref-23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.str.2015.03.012","article-title":"The activation mechanism of 2\u2019-5\u2019-Oligoadenylate synthetase gives new insights into OAS\/cGAS triggers of innate immunity","volume":"23","author":"Loh\u00f6fener","year":"2015","journal-title":"Structure"},{"key":"10.7717\/peerj.20805\/ref-24","doi-asserted-by":"publisher","first-page":"1536020","DOI":"10.3389\/fimmu.2025.1536020","article-title":"Immunometabolism of tregs: mechanisms, adaptability, and therapeutic implications in diseases","volume":"16","author":"Lu","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.7717\/peerj.20805\/ref-25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.7717\/peerj.20805\/ref-26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nature Methods"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-27","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nature Communications"},{"issue":"2","key":"10.7717\/peerj.20805\/ref-28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nature Genetics"},{"key":"10.7717\/peerj.20805\/ref-29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annual Review of Immunology"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/tlcr.2018.02.03","article-title":"Targeting DNA damage repair in small cell lung cancer and the biomarker landscape","volume":"7","author":"Sen","year":"2018","journal-title":"Translational Lung Cancer Research"},{"issue":"3","key":"10.7717\/peerj.20805\/ref-31","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1002\/imt2.36","article-title":"Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform","volume":"1","author":"Shen","year":"2022","journal-title":"Imeta"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.7717\/peerj.20805\/ref-33","doi-asserted-by":"publisher","first-page":"215583","DOI":"10.1016\/j.canlet.2022.215583","article-title":"TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression","volume":"532","author":"Shi","year":"2022","journal-title":"Cancer Letters"},{"issue":"5","key":"10.7717\/peerj.20805\/ref-34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4149\/neo_2018_181020N786","article-title":"Identification of key pathways and genes changes in pancreatic cancer cells (BXPC-3) after cross-talk with primary pancreatic stellate cells using bioinformatics analysis","volume":"66","author":"Tang","year":"2019","journal-title":"Neoplasma"},{"issue":"9","key":"10.7717\/peerj.20805\/ref-35","doi-asserted-by":"publisher","first-page":"e1526\u2013e1537","DOI":"10.1002\/onco.13829","article-title":"Homologous recombination deficiency: cancer predispositions and treatment implications","volume":"26","author":"Toh","year":"2021","journal-title":"Oncologist"},{"issue":"8","key":"10.7717\/peerj.20805\/ref-36","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.Can-06-4250","article-title":"Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation","volume":"67","author":"Tsai","year":"2007","journal-title":"Cancer Research"},{"issue":"12","key":"10.7717\/peerj.20805\/ref-37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ph15121475","article-title":"Targeting the DNA damage response machinery for lung cancer treatment","volume":"15","author":"Venugopala","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.7717\/peerj.20805\/ref-38","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3390\/cimb45030135","article-title":"The landscape and therapeutic targeting of BRCA1, BRCA2 and other DNA damage response genes in pancreatic cancer","volume":"45","author":"Voutsadakis","year":"2023","journal-title":"Current Issues in Molecular Biology"},{"issue":"2","key":"10.7717\/peerj.20805\/ref-39","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7150\/thno.105423","article-title":"B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications","volume":"15","author":"Wu","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/ijms23010348","article-title":"Homologous recombination deficiencies and hereditary tumors","volume":"23","author":"Yamamoto","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.7717\/peerj.20805\/ref-42","doi-asserted-by":"publisher","first-page":"9089397","DOI":"10.1155\/2022\/9089397","article-title":"Identification of significant secreted or membrane-located proteins in laryngeal squamous cell carcinoma","volume":"2022","author":"Yan","year":"2022","journal-title":"Journal of Immunology Research"},{"issue":"8","key":"10.7717\/peerj.20805\/ref-43","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.21037\/tcr-22-698","article-title":"Development of multivariable risk signature based on four immune-related RNA-binding proteins to predict survival and immune status in lung adenocarcinoma","volume":"11","author":"You","year":"2022","journal-title":"Translational Cancer Research"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12957-018-1475-6","article-title":"Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer","volume":"16","author":"Yu","year":"2018","journal-title":"World Journal of Surgical Oncology"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-023-01877-w","article-title":"Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer","volume":"22","author":"Zeng","year":"2023","journal-title":"Molecular Cancer"},{"key":"10.7717\/peerj.20805\/ref-46","doi-asserted-by":"publisher","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-024-03898-w","article-title":"Targeting OAS3 for reversing M2d infiltration and restoring anti-tumor immunity in pancreatic cancer","volume":"74","author":"Zhang","year":"2024","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10.7717\/peerj.20805\/ref-48","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12885-020-07034-6","article-title":"Prognostic characterization of OAS1\/OAS2\/OAS3\/OASL in breast cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.7717\/peerj.20805\/ref-49","doi-asserted-by":"publisher","first-page":"152064","DOI":"10.1016\/j.bbrc.2025.152064","article-title":"IRF2-driven upregulation of OAS3 promotes AML cell proliferation by modulating the JAK-STAT signaling pathway","volume":"772","author":"Zhang","year":"2025","journal-title":"Biochemical and Biophysical Research Communications"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20805.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20805.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20805.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:39:59Z","timestamp":1770885599000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":49,"alternative-id":["10.7717\/peerj.20805"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20805","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"e20805"}}